Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Zoledronic acid increases the antitumor effect of gefitinib treatment for non-small cell lung cancer with EGFR mutations.

Oncology reports - 1 Jun 2016

Feng Chengjun, Liu Xiaoke, Li Xiaoyu, Guo Fuchun, Huang Chuying, Qin Qing, Wang Yongsheng

Abstract excerpt

Non-small cell lung cancer (NSCLC) patients with epithelial growth factor receptor (EGFR) mutations and bone metastases are often concurrently administered tyrosine kinase inhibitors (TKIs) and bisphosphonates. Yet, the effects and mechanisms of these agents are unclear. In the present study, we aimed to ascertain whether zoledronic acid (ZA) increases the antitumor effects of gefitinib treatment on NSCLC with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Cycle
Share to Diphosphonates

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Synergism

Share to Gefitinib

Share to Imidazoles

Share to Mice, Inbred BALB C

Share to Quinazolines

Share to STAT3 Transcription Factor

Source

Identifiers

PMID: 27109760
DOI: 10.3892/or.2016.4741

Genes

EGFR
STAT3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Zoledronic acid increases the antitumor effect of gefitinib treatment for non-small cell lung cancer with EGFR mutations.PMID 27109760Read ↗

Bisphosphonates enhance antitumor effect of EGFR-TKIs in patients with advanced EGFR mutant NSCLC and bone metastases.Semantic proximity Read ↗

Bisphosphonates enhance EGFR-TKIs efficacy in advanced NSCLC patients with EGFR activating mutation: A retrospective study.Semantic proximity Read ↗

KRAS-mutation status dependent effect of zoledronic acid in human non-small cell cancer preclinical models.Semantic proximity Read ↗

STAT3 inhibitor BBI608 enhances the antitumor effect of gefitinib on EGFR-mutated non-small cell lung cancer cells.Semantic proximity Read ↗

Effects of Afatinib on Development of Non-Small-Cell Lung Cancer by Regulating Activity of Wnt/β-Catenin Signaling Pathway.Semantic proximity Read ↗

Ethacrynic Acid Enhances the Antitumor Effects of Afatinib in EGFR/T790M-Mutated NSCLC by Inhibiting WNT/Beta-Catenin Pathway Activation.Semantic proximity Read ↗

Inhibition of DNA‑PK by gefitinib causes synergism between gefitinib and cisplatin in NSCLC.Semantic proximity Read ↗

Autophagy Inhibition Overcomes the Antagonistic Effect Between Gefitinib and Cisplatin in Epidermal Growth Factor Receptor Mutant Non--Small-Cell Lung Cancer Cells.Semantic proximity Read ↗

Synergistic inhibitory effects by the combination of gefitinib and genistein on NSCLC with acquired drug-resistance in vitro and in vivo.Semantic proximity Read ↗

Knockdown of TRAF1 in NSCIC Contributes Gefitinib Sensitivity by Promoting G2/M Cell Cycle ArrestSemantic proximity Read ↗

Schedule-dependent synergistic interaction between docetaxel and gefitinib in NSCLC cell lines regardless of the mutation status of EGFR and KRAS and its molecular mechanisms.Semantic proximity Read ↗

Enhanced gefitinib-induced repression of the epidermal growth factor receptor pathway by ataxia telangiectasia-mutated kinase inhibition in non-small-cell lung cancer cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.